摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(9R,10R)-2-(1,1-dibromoethyl)-8,8-dimethyl-4-oxo-9-[(1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carbonyl]oxy-9,10-dihydropyrano[2,3-f]chromen-10-yl] (1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate | 1253849-50-1

中文名称
——
中文别名
——
英文名称
[(9R,10R)-2-(1,1-dibromoethyl)-8,8-dimethyl-4-oxo-9-[(1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carbonyl]oxy-9,10-dihydropyrano[2,3-f]chromen-10-yl] (1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate
英文别名
——
[(9R,10R)-2-(1,1-dibromoethyl)-8,8-dimethyl-4-oxo-9-[(1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carbonyl]oxy-9,10-dihydropyrano[2,3-f]chromen-10-yl] (1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate化学式
CAS
1253849-50-1
化学式
C36H40Br2O11
mdl
——
分子量
808.515
InChiKey
ZKEGTABJCUWDGM-WBWFEWFTSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.3
  • 重原子数:
    49
  • 可旋转键数:
    7
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    141
  • 氢给体数:
    0
  • 氢受体数:
    11

反应信息

  • 作为产物:
    描述:
    3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyl-2-ethyldihydropyrano[2,3-f]chromone 在 N-溴代丁二酰亚胺(NBS)间氯过氧苯甲酸 作用下, 以 四氯化碳 为溶剂, 反应 5.0h, 以25%的产率得到
    参考文献:
    名称:
    Anti-AIDS agents 79. Design, synthesis, molecular modeling and structure–activity relationships of novel dicamphanoyl-2′,2′-dimethyldihydropyranochromone (DCP) analogs as potent anti-HIV agents
    摘要:
    In a continued study, 23 3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP) derivatives (5-27) were synthesized, and screened for anti-HIV activity against both a non-drug-resistant NL4-3 strain and multiple reverse transcriptase (RT) inhibitor-resistant (RTMDR-1) strain, using 2-EDCP (4) and 2-MDCP (35) as controls. New DCP analogs 5, 9, 14, and 22 exhibited potent anti-HIV activity against HIV(NL4-3) with EC(50) and therapeutic index (TI) values ranging from 0.036 mu M to 0.14 mu M and from 110 to 420, respectively. Compounds 5 and 9 also exhibited good activity against RTMDR-1 (EC(50) 0.049 and 0.054 mu M; TI 310 and 200, respectively), and were twofold more potent than the leads 4 and 35 (EC(50) 0.11 and 0.19 mu M; TI 60 and 58, respectively). Evaluation of water solubility showed that 5 and 22 were 5-10 times more water soluble than 4. Quantitative structure-activity relationship (QSAR) modeling results were first performed on this compound type, and the models should aid in design of future anti-HIV DCP analogs and potential clinical drug candidates. (c) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.07.065
点击查看最新优质反应信息